30.60
전일 마감가:
$31.14
열려 있는:
$30.64
하루 거래량:
604.40K
Relative Volume:
0.64
시가총액:
$2.51B
수익:
$399.58M
순이익/손실:
$-54.04M
주가수익비율:
-40.80
EPS:
-0.75
순현금흐름:
$40.13M
1주 성능:
-4.79%
1개월 성능:
-3.83%
6개월 성능:
-7.61%
1년 성능:
+57.33%
Veracyte Inc Stock (VCYT) Company Profile
명칭
Veracyte Inc
전화
(650) 243-6300
주소
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
VCYT을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
VCYT
Veracyte Inc
|
30.60 | 2.51B | 399.58M | -54.04M | 40.13M | -0.75 |
![]()
TMO
Thermo Fisher Scientific Inc
|
421.85 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
![]()
DHR
Danaher Corp
|
184.96 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
![]()
IDXX
Idexx Laboratories Inc
|
406.65 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
![]()
A
Agilent Technologies Inc
|
100.26 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
![]()
IQV
Iqvia Holdings Inc
|
141.22 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-20 | 개시 | Craig Hallum | Buy |
2024-12-05 | 다운그레이드 | Goldman | Buy → Neutral |
2024-11-15 | 개시 | Wolfe Research | Outperform |
2024-10-16 | 개시 | UBS | Buy |
2024-10-10 | 개시 | Guggenheim | Buy |
2024-02-23 | 재확인 | Needham | Buy |
2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2023-01-05 | 개시 | Scotiabank | Sector Outperform |
2022-01-07 | 개시 | Stephens | Overweight |
2021-11-18 | 재개 | Goldman | Buy |
2021-06-15 | 개시 | Raymond James | Outperform |
2021-02-18 | 재개 | Needham | Buy |
2021-01-28 | 개시 | Truist | Buy |
2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
2020-09-09 | 개시 | Morgan Stanley | Underweight |
2019-07-31 | 개시 | Lake Street | Buy |
2019-07-02 | 개시 | Needham | Buy |
2018-11-29 | 다운그레이드 | Janney | Buy → Neutral |
2018-10-31 | 업그레이드 | Janney | Neutral → Buy |
2017-11-07 | 다운그레이드 | Janney | Buy → Neutral |
2017-11-07 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
2017-08-31 | 재개 | BTIG Research | Buy |
2016-11-14 | 재개 | Leerink Partners | Outperform |
2015-12-18 | 개시 | Cantor Fitzgerald | Buy |
2015-06-11 | 재확인 | Leerink Partners | Outperform |
2013-11-26 | 개시 | William Blair | Outperform |
모두보기
Veracyte Inc 주식(VCYT)의 최신 뉴스
Veracyte data joins NCI SEER database for research By Investing.com - Investing.com India
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release - Business Wire
Should You Continue to Hold Veracyte Stock in Your Portfolio? - MSN
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025 | VCYT Stock News - GuruFocus
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025 - Business Wire
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Here's Why Veracyte (VCYT) is a Strong Growth Stock - Yahoo Finance
Veracyte And 2 More Stocks That Might Be Trading Below Their Estimated Value - Yahoo Finance
Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago - MSN
Veracyte (VCYT) Just Overtook the 20-Day Moving Average - Yahoo Finance
Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength? - Nasdaq
Guggenheim cuts Veracyte stock price target to $37, keeps Buy rating By Investing.com - Investing.com South Africa
Guggenheim cuts Veracyte stock price target to $37, keeps Buy rating - Investing.com Australia
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Veracyte Scores Relative Strength Rating Upgrade; Hits Key Threshold - MSN
Veracyte (VCYT) Introduces AI-Powered Cancer Detection – Faster and More Accurate Than Ever! - Insider Monkey
9 AI News and Ratings on Investors’ Radar - Insider Monkey
Craig-Hallum bullish on Veracyte, initiates with a Buy - MSN
Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade - Yahoo
New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer - 01net
Veracyte Cancer Diagnostic Platform Shows Higher Specificity Than Blood Tests - MarketScreener
Veracyte (VCYT) Shares Cross Above 200 DMA - Nasdaq
Veracyte says new data demonstrate accuracy of WGS-based platform - TipRanks
New Data Demonstrate Accuracy Of Veracyte's Whole-Genome Sequencing-Based Mrd Testing Platform For Muscle-Invasive Bladder Cancer - Marketscreener.com
5 Analysts Assess Veracyte: What You Need To Know - Benzinga
Craig-Hallum initiates Veracyte stock with Buy, sets $45 target By Investing.com - Investing.com South Africa
Craig-Hallum initiates Veracyte stock with Buy, sets $45 target - Investing.com India
Craig-Hallum Initiates Veracyte at Buy With $45 Price Target -March 20, 2025 at 07:28 am EDT - Marketscreener.com
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25 - BioSpace
Veracyte's Decipher, MRD tests highlights to be presented at EAU25 -March 19, 2025 at 05:05 pm EDT - Marketscreener.com
Veracyte's Cancer Detection Tests Prove Powerful in Major Clinical StudiesNew Product Coming - StockTitan
Veracyte Stock Surges 45.6% in a Year: What's Driving the Rally? - Yahoo Finance
Analyst Sees Bottom For Myriad Genetics Stock, Issues UpgradeMyriad Genetics (NASDAQ:MYGN) - Benzinga
Veracyte’s chief commercial officer John Leite sells $234,629 in stock By Investing.com - Investing.com Canada
Veracyte’s chief commercial officer John Leite sells $234,629 in stock - Investing.com
Veracyte (VCYT) Surged on Reporting Strong Earnings - Insider Monkey
Veracyte Inc to Host Earnings Call - ACCESS Newswire
Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality - Simply Wall St
29,779 Shares in Veracyte, Inc. (NASDAQ:VCYT) Purchased by Proficio Capital Partners LLC - Defense World
Veracyte Inc (VCYT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):